XJPX
2269
Market cap6.42bUSD
Jul 10, Last price
3,771.00JPY
1D
-1.90%
1Q
-3.38%
Jan 2017
-58.83%
IPO
128.55%
Name
Meiji Holdings Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Meiji Holdings Co., Ltd., an international enterprise headquartered in Tokyo, Japan, was established in 1916. Through its various subsidiaries, the company specializes in the global manufacturing and distribution of a broad spectrum of products across the food, confectionery, nutritional, and pharmaceutical sectors. Its business activities are distinctly categorized into two core divisions: Food and Pharmaceutical. The Food segment encompasses a wide array of products, including dairy items such as yogurt, cheese, drinking milk, butter, margarine, cream, and ice cream. It also offers various beverages, ready-to-eat meals, and an extensive selection of confectioneries like chocolates, gummy products, and chewing gums. Nutritional offerings within this segment comprise sports nutrition products, infant formula, liquid dietary supplements, and beauty-focused supplements. Additionally, it provides essential ingredients like corn sweeteners and sugar, animal feed, and crucial transportation and distribution services. The Pharmaceutical segment is dedicated to the development and commercialization of medications, including treatments for infectious diseases and central nervous system disorders, alongside a portfolio of generic and over-the-counter (OTC) drugs. This division also serves as a significant provider of human and animal vaccines, blood plasma products, and a range of agricultural and livestock chemicals. For veterinary applications, Meiji offers a comprehensive suite of products for livestock and fisheries, featuring antimicrobial injections, disinfectants, oral medications, insecticides, dewormers, pain relievers, anti-inflammatory agents, hemostatic compounds, and breeding aids. Furthermore, it produces insecticides, metabolites, feed additives, and blended feeds, alongside specialized health solutions for companion animals, such as anesthetics, painkillers, anti-parasitic and gastrointestinal drugs, antibacterial agents, antiplasmin agents, vitamin E preparations, and dietary supplements.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||